Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Biohaven Pharmaceutical(BHVN) the EBIT is -124.9 M (+41%), Miss estimate;the EPS is -0.91 (+53.09%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.12B41.00%
-0.12B42.96%
-0.00B1.96%
EPSMiss expectations
-0.9153.09%
-0.763960.62%
-0.14617.53%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf